While it remains to be validated if VEGFR2 inhibition would increase the radiation sensitivity in glioma patients, VEGFR2 inhibition has been shown to enhanced cell sensitivity to chemotherapy in a PGC1α-dependent manner in acute myeloid leukaemia [36]. Here, PPARGC1A is linked to central nervous system cancer.